Innovator’s Pitch Challenge

Vote for Us

Interested in Connecting? Please contact:
David Kalergis
CEO
dkalergis@atelerixlifesciences.com

Message the company or request a 1:1 meeting here

Atelerix Life Sciences Inc. is a preclinical biotech company developing a platform technology of new drugs targeting unmet medical needs arising from the opioid crisis. This novel drug family, including lead compound ATLX-0199 (also called Sudaxine), addresses death and morbidity from opioid-induced respiratory depression (OIRD) and other opioid-related conditions. The current approach to side effects from opioids is to administer opioid receptor antagonists such as naloxone, which can reverse these life-threatening conditions. These, however, carry significant risks and limitations, particularly as they suppress pain control, making them problematic in the surgical setting. Our solution is found within the new platform of small molecule drugs called Active Thiol-Based Compounds (ATBCs) targeted at safely preventing or reversing opioid-induced side effects via a novel molecular pathway. Sudaxine, Atelerix’s lead drug candidate, is designed to reverse OIRD while preserving pain relief, with first uses targeted in the perioperative hospital setting.

Pitch Video

Slide Deck